BioCentury
ARTICLE | Clinical News

Sulforaphane: Phase II started

May 9, 2016 7:00 AM UTC

Evgen began the double-blind, placebo-controlled, U.K. Phase II SAS trial to evaluate 300 mg oral SFX-01 twice daily for up to 28 days plus nimodipine in about 90 patients. SFX-01 is administered as c...